MedTrace Logo

Effects of Gut Peptides on Bone Remodeling. KS-4-Diabetes-19

NCT03867656 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2020-11-04

No results posted yet for this study

Summary

Both GLP-2 and GIP reduce the bone resorption (measured as CTX) in healthy persons. In this study, we will investigate wether GLP-2 and GIP is reducing CTX in persons with type 2 diabetes.

Conditions

Interventions

OTHER

GLP-2

GLP-2 injection

OTHER

GIP

GIP injection

OTHER

Placebo

Placebo injection

Sponsors & Collaborators

  • Hvidovre University Hospital

    collaborator OTHER

  • University of Copenhagen

    lead OTHER

Principal Investigators

  • Mette Rosenkilde, MD · University of Copenhagen

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
SINGLE
Model
CROSSOVER

Eligibility

Min Age
25 Years
Max Age
70 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-02-26
Primary Completion
2020-06-26
Completion
2020-06-26

Countries

  • Denmark

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03867656 on ClinicalTrials.gov